drugset / Trial / NCT03356808
Antigen-specific T Cells Against Lung Cancer
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this clinical trial is to assess the feasibility, safety and efficacy of cancer antigen-specific T cells targeting lung cancer. The cancer targeting antigens are identified through immunostaining of patient's cancer specimens. Another goal of the study is to learn more about the persistence and function of the ex vivo manipulated antigen-specific T cells in the body.
Timeline
- Start
- 2026-06-01
- Primary completion
- 2029-12-31
- Completion
- 2030-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lung cancer-specific T cells | Cell therapy | 1e+06 cells/kg | Intravenous |
| Subject | Lung cancer-specific T cells | Cell therapy | 1e+07 cells/kg | Intravenous |